US 11,680,266 B2
Endomucin inhibitor as an anti-angiogenic agent
Patricia A. D'Amore, Newton, MA (US); Magali Saint-Geniez, Somerville, MA (US); and Cindy Park-Windhol, Newton, MA (US)
Assigned to The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed by The Schepens Eye Research Institute, Inc., Boston, MA (US)
Filed on Dec. 2, 2020, as Appl. No. 17/110,248.
Application 17/110,248 is a division of application No. 16/089,990, granted, now 10,883,108, previously published as PCT/US2017/025468, filed on Mar. 31, 2017.
Claims priority of provisional application 62/316,481, filed on Mar. 31, 2016.
Prior Publication US 2021/0163955 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61P 27/02 (2006.01); A61P 9/00 (2006.01)
CPC C12N 15/1138 (2013.01) [A61K 31/713 (2013.01); A61P 9/00 (2018.01); A61P 27/02 (2018.01); C12N 2310/14 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for reducing neovascularization in an ocular tissue, comprising contacting said ocular tissue with an inhibitor of endomucin (EMCN) expression or activity, wherein said inhibitor comprises an EMCN-specific antibody or fragment thereof.